# Swing Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/swing-therapeutics

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.swingtherapeutics.com
- Total disclosed funding: $19M
- Latest round: Series A (Jan 24, 2022)
- Investors on record: 8

## About

Swing Therapeutics, Inc. is a California-based company founded in 2019, focused on developing innovative digital therapies to enhance the quality of life for patients with chronic illnesses, particularly fibromyalgia.Swing Therapeutics, Inc., headquartered in San Francisco, California, specializes in creating digital therapies. Founded by Nelson Mitchell, the company has received funding with a Series A round in January 2022, raising USD 10.29 mn led by JAZZ Venture Partners. The company has successfully completed 2 deals to date, with a total amount raised of USD 10.29 mn and a current valuation of USD 33.799 mn.Swing Therapeutics specializes in developing digital therapies aimed at improving the quality of life for individuals with chronic illnesses, particularly those suffering from fibromyalgia. Their flagship product, Stanza, is an FDA-cleared digital therapy designed specifically for the management of fibromyalgia symptoms. This therapy functions by delivering evidence-based behavioral treatments through a smartphone application, allowing users to engage in 15-minute sessions at their convenience. The primary end users are patients diagnosed with fibromyalgia, and the service is available by prescription, catering to individuals seeking non-pharmacological treatment options. Swing Therapeutics aims to extend its reach beyond the United States, targeting markets in Europe and other regions where chronic pain management is a growing concern.Swing Therapeutics generates revenue primarily through the prescription of its digital therapy product, Stanza. The transaction model is direct-to-consumer, with patients accessing the therapy via their healthcare providers who prescribe the treatment based on individual needs. The company positions its service as a subscription-based offering, aimed at providing ongoing access to therapeutic content and support. Although specific pricing details are not disclosed, the structure implies a recurring revenue model where patients can engage with the therapy over an extended period. This approach not only facilitates adherence to treatment but also enhances the overall effectiveness of the therapy as users are encouraged to integrate it into their daily routines.Swing Therapeutics plans to leverage the recent funding of USD 10.29 mn raised on January 24, 2022, to expand its product and service offerings. The company is focused on launching new products aimed at enhancing the therapeutic experience for users and is targeting expansion into European markets and other regions where chronic pain management solutions are needed. The additional capital will support these initiatives as the company seeks to grow its reach and effectiveness in addressing fibromyalgia and similar chronic conditions.

## Funding rounds

- Series A, Jan 24, 2022, $10M — AME Cloud Ventures, Alumni Ventures Group, JAZZ Venture Partners, Gaingels, Mana Ventures, Asahi Kasei Corporate Venture Capital, Metrodora Ventures, Kicker Ventures
- Seed, Aug 11, 2021, $9M — JAZZ Venture Partners

## Investors

- JAZZ Venture Partners (https://capitalatlas.ai/funds/jazz-venture-partners) — Seed, Series A
- AME Cloud Ventures (https://capitalatlas.ai/funds/ame-cloud-ventures) — Series A
- Alumni Ventures Group (https://capitalatlas.ai/funds/alumni-ventures-group) — Series A
- Gaingels (https://capitalatlas.ai/funds/gaingels) — Series A
- Mana Ventures (https://capitalatlas.ai/funds/mana-ventures) — Series A
- Asahi Kasei Corporate Venture Capital — Series A
- Metrodora Ventures (https://capitalatlas.ai/funds/metrodora-ventures) — Series A
- Kicker Ventures (https://capitalatlas.ai/funds/kicker-ventures) — Series A